β细胞的清白推定:为何它们是1型糖尿病的易感自身免疫靶点?
文章提出1型糖尿病的发病机制不仅涉及自身免疫攻击者,还涉及β细胞靶点,二者在胰腺内外进行冲突性对话。自身免疫CD8+ T细胞在1型糖尿病患者和健康个体中以相似频率循环,提示存在普遍良性胰岛自身免疫,其进展为1型糖尿病可能至少部分依赖于β细胞更高的易感性。作者认为这种自身免疫易感性源于β细胞生物学特征,如高产胰岛素及颗粒蛋白的应激、密集血管化及产物直接分泌入血,相关基因变异(如MDA5、TYK2、PTPN2)与环境线索(如病毒感染)交互作用,可能驱动局部炎症加剧和β细胞进行性丢失。
要点
- 自身免疫CD8+ T细胞在1型糖尿病患者与健康人中循环频率相似,提示存在普遍良性胰岛自身免疫。
- β细胞高频率生产胰岛素及颗粒蛋白的应激、密集血管化及直接分泌入血构成其自身免疫易感性基础。
- MDA5、TYK2、PTPN2等基因变异与环境线索(如病毒感染)交互作用,可能加剧局部炎症和β细胞丢失。
核心结论
- 1型糖尿病的进展可能至少部分依赖于β细胞更高的自身免疫易感性,β细胞在疾病发生和/或放大中起关键主动作用。
研究设计与样本
- 本文为综述/观点类文章,未报告系统检索范围或样本量。
主要发现
- 自身免疫CD8+ T细胞是β细胞破坏的最终介质,在1型糖尿病患者和健康个体中以相似频率循环。
- β细胞自身免疫易感性源于高产胰岛素及颗粒蛋白的应激、密集血管化及产物直接分泌入血等生物学特征。
- MDA5、TYK2、PTPN2等基因变异与环境线索(如病毒感染)交互作用,可能驱动局部炎症加剧和β细胞进行性丢失。
- β细胞启动未折叠蛋白反应等代偿反应,长期可变为有害。
- 免疫驱动因素与β细胞驱动因素的相对贡献可能不同,可能存在表型亚型(内型)。
临床怎么用
- 主张使用自身免疫和β细胞应激的循环生物标志物进行疾病分期。
- 支持实施免疫调节和β细胞保护的双重治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
It is increasingly appreciated that the pathogenic mechanisms of type 1 diabetes involve both the autoimmune aggressors and their beta cell targets, which engage in a conflicting dialogue within and possibly outside the pancreas. Indeed, autoimmune CD8+ T cells, which are the final mediators of beta cell destruction, circulate at similar frequencies in type 1 diabetic and healthy individuals. Hence a universal state of 'benign' islet autoimmunity exists, and we hypothesise that its progression to type 1 diabetes may at least partially rely on a higher vulnerability of beta cells, which play a key, active role in disease development and/or amplification. We posit that this autoimmune vulnerability is rooted in some features of beta cell biology: the stress imposed by the high rate of production of insulin and other granule proteins, their dense vascularisation and the secretion of their products directly into the bloodstream. Gene variants that may predispose individuals to this vulnerability have been identified, e.g. MDA5, TYK2, PTPN2. They interact with environmental cues, such as viral infections, that may drive this genetic potential towards exacerbated local inflammation and progressive beta cell loss. On top of this, beta cells set up compensatory responses, such as the unfolded protein response, that become deleterious in the long term. The relative contribution of immune and beta cell drivers may vary and phenotypic subtypes (endotypes) are likely to exist. This dual view argues for the use of circulating biomarkers of both autoimmunity and beta cell stress for disease staging, and for the implementation of both immunomodulatory and beta cell-protective therapeutic strategies. Graphical abstract.
引用
- Mallone R, Eizirik DL. Presumption of innocence for beta cells: why are they vulnerable autoimmune targets in type 1 diabetes? Diabetologia. 2020. PMID: 32894310. doi:10.1007/s00125-020-05176-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。